Startup | May 20, 2024
IIHMR Start-ups inks MoU with BMCHRC & HCG Hospital
The collaboration aims to bolster healthcare entrepreneurship
The collaboration aims to bolster healthcare entrepreneurship
The funds raised from the Whitathon run are utilized to treat underprivileged children suffering from Retinoblastoma
At the recommended Phase 3 dose of 200 mg vepdegestrant in combination with palbociclib, patients achieved a median progression-free survival of 13.9 months
Data showed that the primary endpoint of recurrence-free survival (RFS) met the pre-specified futility criteria
Lupin updates on shipment of Mirabegron ER Tablets
First BTK inhibitor to show favourable trend in overall survival vs. standard-of-care chemoimmunotherapy in this setting
Eugia Pharma Specialities receives 7 observations from USFDA for Unit II
GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)
Late-breaker Phase 3 STRIDE-10 trial presented as an oral presentation at European Society of Clinical Microbiology and Infectious Diseases
Recommendation based on CAPItello-291 results which showed the Truqap combination reduced the risk of disease progression or death by 50%
Subscribe To Our Newsletter & Stay Updated
